314 related articles for article (PubMed ID: 32056400)
1. 1,25-dihydroxy Vitamin D3 and Interleukin-6 Blockade Synergistically Regulate Rheumatoid Arthritis by Suppressing Interleukin-17 Production and Osteoclastogenesis.
Kim H; Baek S; Hong SM; Lee J; Jung SM; Lee J; Cho M; Kwok SK; Park SH
J Korean Med Sci; 2020 Feb; 35(6):e40. PubMed ID: 32056400
[TBL] [Abstract][Full Text] [Related]
2. [1,25(OH)2-Vitamin-D3 attenuates Th17-related cytokines expression in peripheral blood mononuclear cells in patients with early-diagnosed rheumatoid arthritis].
Wen H; Luo J; Zhang X; Zhang C; Zhao X; Wang X; Li X
Zhonghua Nei Ke Za Zhi; 2015 Apr; 54(4):317-21. PubMed ID: 26268060
[TBL] [Abstract][Full Text] [Related]
3. The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab.
Diaz-Torne C; Ortiz MDA; Moya P; Hernandez MV; Reina D; Castellvi I; De Agustin JJ; Fuente D; Corominas H; Sanmarti R; Zamora C; Cantó E; Vidal S
Semin Arthritis Rheum; 2018 Jun; 47(6):757-764. PubMed ID: 29157669
[TBL] [Abstract][Full Text] [Related]
4. Role of vitamin D supplementation in improving disease activity in rheumatoid arthritis: An exploratory study.
Chandrashekara S; Patted A
Int J Rheum Dis; 2017 Jul; 20(7):825-831. PubMed ID: 26481198
[TBL] [Abstract][Full Text] [Related]
5. Leucine-rich α2 -glycoprotein as a potential biomarker for joint inflammation during anti-interleukin-6 biologic therapy in rheumatoid arthritis.
Fujimoto M; Serada S; Suzuki K; Nishikawa A; Ogata A; Nanki T; Hattori K; Kohsaka H; Miyasaka N; Takeuchi T; Naka T
Arthritis Rheumatol; 2015 May; 67(8):2056-60. PubMed ID: 25917892
[TBL] [Abstract][Full Text] [Related]
6. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis.
Shimamoto K; Ito T; Ozaki Y; Amuro H; Tanaka A; Nishizawa T; Son Y; Inaba M; Nomura S
J Rheumatol; 2013 Jul; 40(7):1074-81. PubMed ID: 23637318
[TBL] [Abstract][Full Text] [Related]
7. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
[TBL] [Abstract][Full Text] [Related]
8. Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis.
Levi M; Grange S; Frey N
J Clin Pharmacol; 2013 Feb; 53(2):151-9. PubMed ID: 23436260
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology of tocilizumab for the treatment of patients with rheumatoid arthritis.
Zhang X; Peck R
Expert Rev Clin Pharmacol; 2011 Sep; 4(5):539-58. PubMed ID: 22114882
[TBL] [Abstract][Full Text] [Related]
10. Changes in serum interleukin-6 levels as possible predictor of efficacy of tocilizumab treatment in rheumatoid arthritis.
Aizu M; Mizushima I; Nakazaki S; Nakashima A; Kato T; Murayama T; Kato S; Katsuki Y; Ogane K; Fujii H; Yamada K; Nomura H; Yachie A; Yamagishi M; Kawano M
Mod Rheumatol; 2018 Jul; 28(4):592-598. PubMed ID: 28880691
[TBL] [Abstract][Full Text] [Related]
11. [New approaches to pharmacotherapy for rheumatoid arthritis: perspective for use of tocilizumab (monoclonal antibodies to interleukin-6 receptor)].
Nasonov EL
Ter Arkh; 2010; 82(5):64-71. PubMed ID: 20597275
[TBL] [Abstract][Full Text] [Related]
12. Infliximab equivalently suppresses oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis.
Kizaki K; Yamashita F; Hayashi T; Funakoshi N
Int J Rheum Dis; 2018 Oct; 21(10):1815-1821. PubMed ID: 27778459
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: the role of acute-phase reactants.
Smolen JS; Aletaha D
Arthritis Rheum; 2011 Jan; 63(1):43-52. PubMed ID: 21204103
[TBL] [Abstract][Full Text] [Related]
14. Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.
Bijlsma JWJ; Welsing PMJ; Woodworth TG; Middelink LM; Pethö-Schramm A; Bernasconi C; Borm MEA; Wortel CH; Ter Borg EJ; Jahangier ZN; van der Laan WH; Bruyn GAW; Baudoin P; Wijngaarden S; Vos PAJM; Bos R; Starmans MJF; Griep EN; Griep-Wentink JRM; Allaart CF; Heurkens AHM; Teitsma XM; Tekstra J; Marijnissen ACA; Lafeber FPJ; Jacobs JWG
Lancet; 2016 Jul; 388(10042):343-355. PubMed ID: 27287832
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study.
Genovese MC; McKay JD; Nasonov EL; Mysler EF; da Silva NA; Alecock E; Woodworth T; Gomez-Reino JJ
Arthritis Rheum; 2008 Oct; 58(10):2968-80. PubMed ID: 18821691
[TBL] [Abstract][Full Text] [Related]
16. Low baseline interleukin-17A levels are associated with better treatment response at 12 weeks to tocilizumab therapy in rheumatoid arthritis patients.
Lee SJ; Park W; Park SH; Shim SC; Baek HJ; Yoo DH; Kim HA; Lee SK; Leee YJ; Park YE; Cha HS; Park JK; Lee EY; Lee EB; Song YW
J Immunol Res; 2015; 2015():487230. PubMed ID: 25922848
[TBL] [Abstract][Full Text] [Related]
17. Association between metabolic syndrome, BMI, and serum vitamin D concentrations in rheumatoid arthritis.
Goshayeshi L; Saber H; Sahebari M; Rezaieyazdi Z; Rafatpanah H; Esmaily H; Goshayeshi L
Clin Rheumatol; 2012 Aug; 31(8):1197-203. PubMed ID: 22581277
[TBL] [Abstract][Full Text] [Related]
18. Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
Izumi K; Kaneko Y; Hashizume M; Yoshimoto K; Takeuchi T
PLoS One; 2015; 10(12):e0145468. PubMed ID: 26698858
[TBL] [Abstract][Full Text] [Related]
19. Relationships between concomitant biologic DMARDs and prednisolone administration and blood tacrolimus exposure or serum CYP3A4/5-related markers in rheumatoid arthritis patients.
Naito T; Ohshiro J; Sato H; Torikai E; Suzuki M; Ogawa N; Kawakami J
Clin Biochem; 2019 Jul; 69():8-14. PubMed ID: 31077643
[TBL] [Abstract][Full Text] [Related]
20. Hypovitaminosis D in recent onset rheumatoid arthritis is predictive of reduced response to treatment and increased disease activity: a 12 month follow-up study.
Di Franco M; Barchetta I; Iannuccelli C; Gerardi MC; Frisenda S; Ceccarelli F; Valesini G; Cavallo MG
BMC Musculoskelet Disord; 2015 Mar; 16():53. PubMed ID: 25887374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
